


SB 706504

Cat. No.:	HY-108644
CAS No.:	911110-38-8
Molecular Formula:	C ₂₄ H ₁₉ F ₃ N ₈ O
Molecular Weight:	492.46
Target:	p38 MAPK
Pathway:	MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD) ^[1] .
In Vitro	SB 706504(3 μM, 6 h) significantly reduces IL-1β, IL-6, GM-CSF, TNFα and IL-8 mRNA levels in LPS-stimulated monocyte derived macrophages (MDMs) cells ^[1] . SB 706504(3 μM, 6 h) can significantly reduce the level of TNFα induced by LPS in alveolar macrophages (AMs) cells of COPD patients, with an inhibition rate of 67.4% ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lauren M. Kent, et al. Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-[[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl]amino]ethyl)guanidine (SB706504).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA